Galedra

Claims

Search Type State Status Topic Model Order Counting Over

As of snapshot 27745 under ledger-default@0.3.0.

Claim	Type	Assessment	Score	Review checks	References
In the testing cohort, PANXEON combined with CA19-9 detected stage I–II pancreatic ductal adenocarcinoma with 86.8% sensitivity, with false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls.	QUANTITATIVE	Supported	0.9908	1 of 4	179